Hugenix Biologicals Private Limited
Pharmaceutical trading company established in 2020 with headquarters in Delhi.
2020 | Delhi (India) | Active
Hugenix Biologicals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -637.16%
- Ebitda -667.94%
- Net Worth -316.54%
- Total Assets 62.19%
About Hugenix Biologicals
Hugenix Biologicals Private Limited (HBPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 April 2020 (Four years and nine months 30 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sandeep Kumar and Deepika Sharma serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U36999DL2020PTC363487
- Company No.
363487
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Apr 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Who are the key members and board of directors at Hugenix Biologicals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Kumar  | Director | 29-Apr-2020 | Current |
| Deepika Sharma | Director | 15-Jan-2021 | Current |
Financial Performance of Hugenix Biologicals.
Hugenix Biologicals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 637.16% decrease in profit. The company's net worth observed a substantial decline by a decrease of 316.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hugenix Biologicals?
In 2021, Hugenix Biologicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Siddhivinayak Medicine House Llp
Sandeep Kumar and Deepika Sharma are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hugenix Biologicals?
Hugenix Biologicals has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hugenix Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hugenix Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
